Certified by Founder
                                        Lodge
                                        
                                        
                                    
                                    
                                    HEPHAISTOS-Pharma
                                                                                start up
                                                                            
                                    
                                                                                                                                    
                                                                                                France
                                                 -                                                 Orsay, Île-de-France
                                                                                            
                                                                                    - 17/05/2024
 - Seed
 - $11,189,199
 
HEPHAISTOS-Pharma est une startup en biotechnologie développant des immunothérapies anti-tumorales permettant de révolutionner les traitements contre le cancer en décuplant l'efficacité des anticorps monoclonaux et en permettant le traitement de tumeurs incurables.
- Industry Biotechnology
 - Website https://hephaistos-pharma.fr/
 - LinkedIn https://www.linkedin.com/company/hephaistos-pharma/
 
Related People
Frederic CAROFFFounder
                                                    
                                                                                                                France -
                                                         Boulogne-Billancourt, Île-de-France
                                                    
                                                Biotechnology entrepreneur for 10 years, I am currently the CEO of HEPHAISTOS-Pharma, a biotech company developing new immunotherapies in oncology in order to revolutionize the effectiveness of cancer treatments. 
Our ONCO-Boost technology allows us to stimulate patients' immunity to treat cold tumors such as Osteosarcoma, an orphan disease, but also to increase the effectiveness of therapeutic antibodies in combination. 
                                catalyx space |  $5,400,000  | (Nov 4, 2025)
                            
                                Indomo |  $25,000,000  | (Nov 4, 2025)
                                xMEMS |  $21,000,000  | (Nov 4, 2025)
                                            
                                                
                                                    
                                                    
                                                    
                                                
                                                    
                                                
                                                
                                                
                                                    
                                                
                                                
                                                
                                                
                                                
                                                                        
                                Cephia AI |  $4,000,000  | (Nov 4, 2025)
                                                                        
                                Ornn |  $5,700,000  | (Nov 4, 2025)
                                                                        
                                Popai Health |  $11,000,000  | (Nov 4, 2025)
                                                                        
                                Helex |  $3,500,000  | (Nov 4, 2025)
                                                                        
                                AUI™ (Augmented Intelligence) |  $20,000,000  | (Nov 4, 2025)
                                                                        
                                Mem0 |  $24,000,000  | (Oct 30, 2025)
                                                                        
                                FrontlineIQ |  $3,300,000  | (Oct 30, 2025)